

Author: Adis International Limited
Publisher: Adis International
ISSN: 0114-5916
Source: Drug Safety, Vol.28, Iss.7, 2005-01, pp. : 647-647
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Managing the Adverse Effects of Interferon- Therapy in Multiple Sclerosis
Drug Safety, Vol. 22, Iss. 2, 2000-02 ,pp. :






Minimising the Adverse Effects of Ketorolac
Drug Safety, Vol. 22, Iss. 6, 2000-06 ,pp. :


Antidepressants: a comparison of adverse effects
Inpharma, Vol. 1, Iss. 1337, 2002-01 ,pp. :